Mediford Corporation and C2N Diagnostics Partnership Declared on Alzheimer’s Disease Testing

A collaboration has been established between Mediford Corporation division of PHC Holdings Corporation, and C2N Diagnostics to enable Mediford to back up and supply C2N’s PrecivityTM blood testing services and goods for the Japanese research industry.

These days, amyloid PET scans and spinal fluid testing are frequently utilised to aid in the identification of Alzheimer’s disease. By accurately measuring indicators thought to be crucial to the identification and development of Alzheimer’s disease through blood collection, the C2N portfolio of PrecivityTM blood tests seeks to significantly reduce the workload and diagnostic evaluation procedure for clients.

The proportion of Japan’s ageing population that is either suffering with dementia or at an elevated risk of getting it is rising sharply. It is thought that over fifty percent of those exhibiting indicators of dementia are suffering from Alzheimer’s disease.

Mediford Corporation President Stated, “Mediford Corporation has been developing biomarkers for dementia through collaborative research in Japan and expects that C2N’s PrecivityTM blood test technology will be one of the unique tools that will greatly benefit dementia-related research and development in Japan.”

C2N President & CEO explained, “This new collaboration is part of our commitment to provide global access to high quality diagnostic tools that will enable clinical trial researchers and drug developers to better evaluate the newest solutions and products targeting Alzheimer’s disease and related dementias.”